I agree with you that combos will be explored but I also believe NWBO has some of their own ideas up their sleeve already. The danger for big pharma has always been from underestimating what the DCVax platform potential really is and how well prepared NWBO is set to move that potential forward. Remember, what is most important to NWBO is what is least talked about. Just because there aren’t a great many ongoing trials with L or Direct doesn’t mean that they haven’t figured out some very important things from the data they do have and from what they have come to understand from what others have shared with them from their own developments with regard to immunotherapy. When is the last time we talked about INMune Bio? Sooooooo much info to get out and the ability to understand how it all fits together is often limited by focus. This is a disruptive technology and the attempt to harness the implications is going to be very difficult unless a plan has been put in place and I think it has been. Amazing!; ). Best wishes.
Market Data 
Markets 
AI
